Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT04173715
Recruiting Observational

Movement and Behaviours Measurement Study

NCT04173715 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2019-10-14
Last updated
2024-05-08

Condition(s) studied

AgingPhysical FunctionFrailty SyndromePhysical DisabilityLifestyle, Sedentary

Investigational drug(s) / intervention(s)

Older Adults Group.Low Physical Function Status GroupMedium Physical Function Status GroupHigh Physical Function Status Group

Older Adults Group.: Physical activity and energy expenditure quantification

Low Physical Function Status Group: Physical activity and energy expenditure quantification

Medium Physical Function Status Group: Physical activity and energy expenditure quantification

High Physical Function Status Group: Physical activity and energy expenditure quantification

Study summary

There are few studies that already have validated specific raw accelerometer cut-points for people over 65 years old.

The purpose of the present study is to validate raw accelerometer cut points for general people over 65 years old and specific raw accelerometer cut points based on the functional status of older adults over 65 years old.

The study will be carried out with an observational approach. Participants will be divided into 4 groups. First of them will be made grouping all subjects and the rest divided according to their functional status. They will perform different-intensity physical activities while wearing accelerometers attached to their body and wearing a portable gas analyser too. Their intensity will be assessed based on their own Rest Metabolic Rate (RMR). Energy expenditure and accelerations will be matched and, based on that, sedentary behaviour, light physical activity and moderate-to-vigorous physical activity cut-points will be derived.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * 65 years and older * Non-institutionalized * Physical function assessment (SPPB\>3) Exclusion Criteria: * Have started an exercise program. * Mini-Mental Score \< 18. * Presenting any physical activity contraindication.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Universidad de Castilla-La Mancha, Laboratorio de Actividad Física y Función Muscular Toledo Spain Recruiting

More University of Castilla-La Mancha trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04173715 on ClinicalTrials.gov ↗ ← All trials in Spain